search
Back to results

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Regular Human Insulin
Insulin Lispro
Insulin VIAject™ (75%)
Insulin VIAject™ (90%)
Sponsored by
Biodel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Type 2 diabetes mellitus according to the ADA criteria
  2. HbA1c between 6.5 % and 9.9 %
  3. Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3 months
  4. Age between 40 and 75 years
  5. BMI < 40

Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Pre-treatment with insulin within the last 6 months prior to screening
  3. Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks prior to screening
  4. Untreated hypertension stage II-III according to WHO criteria
  5. Planned or anticipated change in antidiabetic and/or concomitant medication during study participation
  6. Total cholesterol > 300 mg/dl (anamnestically)
  7. Major micro- or macrovascular complications as judged by the investigator
  8. Tobacco use within the last 6 months prior to screening
  9. Drugs with major impact on endothelial function like nitrates etc.
  10. History of drug or alcohol abuse which in the opinion of the investigator will impair subject safety or protocol compliance
  11. History of hypersensitivity to the study drugs or to drugs with similar chemical structures
  12. History of severe or multiple allergies
  13. Treatment with any other investigational drug within 3 months prior to screening
  14. Progressive fatal disease
  15. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women and > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator
  16. Pregnancy or breast feeding
  17. Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
  18. Lack of compliance or other similar reason that at the discretion of the investigator precludes satisfactory participation in the study
  19. Hypopotassemia (K<3.5 mmol /l)

Sites / Locations

  • IKFE

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Experimental

Experimental

Arm Label

Regular Human Insulin

Inuslin Lispro (90%)

Insulin VIAject™ (75%)

Insulin VIAject™ (90%)

Arm Description

Single Injection

Single Injection

Single Injection

Single injection

Outcomes

Primary Outcome Measures

Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.

Secondary Outcome Measures

The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.

Full Information

First Posted
February 20, 2009
Last Updated
July 30, 2015
Sponsor
Biodel
search

1. Study Identification

Unique Protocol Identification Number
NCT00849576
Brief Title
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biodel

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the effects of insulin VIAject with Regular Human Insulin and Insulin Lispro on measures of mealtime blood vessel stress and blood flow.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Regular Human Insulin
Arm Type
Active Comparator
Arm Description
Single Injection
Arm Title
Inuslin Lispro (90%)
Arm Type
Active Comparator
Arm Description
Single Injection
Arm Title
Insulin VIAject™ (75%)
Arm Type
Experimental
Arm Description
Single Injection
Arm Title
Insulin VIAject™ (90%)
Arm Type
Experimental
Arm Description
Single injection
Intervention Type
Drug
Intervention Name(s)
Regular Human Insulin
Intervention Description
0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
Intervention Type
Drug
Intervention Name(s)
Insulin Lispro
Intervention Description
90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
Intervention Type
Drug
Intervention Name(s)
Insulin VIAject™ (75%)
Intervention Description
75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Intervention Type
Drug
Intervention Name(s)
Insulin VIAject™ (90%)
Intervention Description
90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Primary Outcome Measure Information:
Title
Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.
Time Frame
0 - 240 minutes
Secondary Outcome Measure Information:
Title
The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.
Time Frame
0 - 240 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes mellitus according to the ADA criteria HbA1c between 6.5 % and 9.9 % Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3 months Age between 40 and 75 years BMI < 40 Exclusion Criteria: Type 1 diabetes mellitus Pre-treatment with insulin within the last 6 months prior to screening Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks prior to screening Untreated hypertension stage II-III according to WHO criteria Planned or anticipated change in antidiabetic and/or concomitant medication during study participation Total cholesterol > 300 mg/dl (anamnestically) Major micro- or macrovascular complications as judged by the investigator Tobacco use within the last 6 months prior to screening Drugs with major impact on endothelial function like nitrates etc. History of drug or alcohol abuse which in the opinion of the investigator will impair subject safety or protocol compliance History of hypersensitivity to the study drugs or to drugs with similar chemical structures History of severe or multiple allergies Treatment with any other investigational drug within 3 months prior to screening Progressive fatal disease History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women and > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator Pregnancy or breast feeding Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner Lack of compliance or other similar reason that at the discretion of the investigator precludes satisfactory participation in the study Hypopotassemia (K<3.5 mmol /l)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Forst, MD
Organizational Affiliation
IKFE Institute for Clinical Research and Development
Official's Role
Principal Investigator
Facility Information:
Facility Name
IKFE
City
Parcusstrasse 8
State/Province
Mainz
ZIP/Postal Code
55116
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

We'll reach out to this number within 24 hrs